Jun 2026 (Q2 FY26) — Aug 6, 2026
Definium Therapeutics Q2 FY26 — Positive Phase III MDD Results & Upcoming GAD Data
Read the full callDefinium Therapeutics (DFTX) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Definium Therapeutics earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | Quarterly, as filed | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -159 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
8 of 9 judged targets kept · 5 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Completion of enrollment in Voyage, Phase III GAD trial | conclude Voyage enrollment in the coming weeks (from 26 February 2026) | Dec 2025 | having completed enrollment in both Voyage and Panorama, our 2 Phase III studies in GAD | Achieved |
| Voyage Phase III GAD top-line data readout | top line Part A readout in the first half of 2026 | Jun 2024 | we anticipate presenting top line results from Voyage, our first Phase III study of DT120 ODT in generalized anxiety disorder, or GAD, during the week of August 10, 2026 | Missed |
| Cash runway — operations funded into 2027 and at least 12 months beyond the first Phase III GAD top-line readout | cash runway into 2027, at least 12 months beyond first Phase III GAD readout | Jun 2024 | we believe this capital is sufficient to fund planned operations into 2030 | Revised Up |
1 of Definium Therapeutics, Inc.'s 14 targets was missed. See which ones, and which are quietly gone. The 3 above are the free sample; 11 more targets are in the full ledger.
Claimed
- Reported positive top-line results from Emerge, the first Phase III study of DT120 ODT in MDD, demonstrating an 8.1 point placebo-adjusted improvement on MADRS at week 6 (p<0.0001), representing the largest treatment effect ever reported in a Phase III MDD study.
- Completed enrollment in both Voyage and Panorama, two Phase III studies in GAD, with top-line results expected in August and September 2026, respectively.
- Strengthened balance sheet with an upsized public offering that generated approximately $805 million in gross proceeds, ending the quarter with $1.1 billion in cash, cash equivalents, and investments.
- Projected cash runway extends into 2030, providing resources for strategic execution and commercialization.
Qualified
Price
$34.26 +0.06% · +$0.02
Performance +171.5% 1Y
1Y: $12.62 on 14 Oct 2025 → $34.26. High $48.45 (9 Jul 2026), low $10.68 (21 Nov 2025).
- Previous close
- $34.24
- 52-week range
- $10.68 – $48.45
- One year
- +170.62%
Overview
- Symbol
- DFTX
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
8 of 9 judged targets kept · 5 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Completion of enrollment in Voyage, Phase III GAD trial | conclude Voyage enrollment in the coming weeks (from 26 February 2026) | Dec 2025 | having completed enrollment in both Voyage and Panorama, our 2 Phase III studies in GAD | Achieved |
| Voyage Phase III GAD top-line data readout | top line Part A readout in the first half of 2026 | Jun 2024 | we anticipate presenting top line results from Voyage, our first Phase III study of DT120 ODT in generalized anxiety disorder, or GAD, during the week of August 10, 2026 | Missed |
| Cash runway — operations funded into 2027 and at least 12 months beyond the first Phase III GAD top-line readout | cash runway into 2027, at least 12 months beyond first Phase III GAD readout | Jun 2024 | we believe this capital is sufficient to fund planned operations into 2030 | Revised Up |
Claimed
- Reported positive top-line results from Emerge, the first Phase III study of DT120 ODT in MDD, demonstrating an 8.1 point placebo-adjusted improvement on MADRS at week 6 (p<0.0001), representing the largest treatment effect ever reported in a Phase III MDD study.
- Completed enrollment in both Voyage and Panorama, two Phase III studies in GAD, with top-line results expected in August and September 2026, respectively.
- Strengthened balance sheet with an upsized public offering that generated approximately $805 million in gross proceeds, ending the quarter with $1.1 billion in cash, cash equivalents, and investments.
- Projected cash runway extends into 2030, providing resources for strategic execution and commercialization.
Qualified
The full ledger
Open Definium Therapeutics, Inc.’s full ledger
A free account opens 5 company ledgers a month. All 14 tracked commitments, with each call’s wording and source.
Call summaries
Dec 2025 (Q4 FY25) — Feb 26, 2026
Definium Therapeutics Q4 FY25 — Pivotal Phase III Readouts Imminent for DT120 ODT
Read the full callEvery analysed call
Definium Therapeutics earnings calls (DFTX)
Financials
What the filings say
Net profit, year on year: −272% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating profit | -25 | -32 | -32 | -41 | -46 | -48 | -59 | -75 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 |
| Net profit | -14 | -35 | -23 | -43 | -67 | -50 | -77 | -159 |
| EPS ($ per share) | -0.18 | — | -0.27 | -0.50 | -0.78 | — | -0.71 | -1.44 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Equity capital | — | — | — | — | 0 | 0 | — |
| Reserves | — | -45 | -138 | -194 | -290 | -399 | -583 |
| Total liabilities | — | 6 | 12 | 19 | 46 | 61 | 108 |
| Investments | — | — | — | — | — | 0 | 154 |
| Total assets | — | 82 | 164 | 170 | 125 | 302 | 440 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -24 | -46 | -50 | -64 | -79 | -132 |
| Cash from investing | — | -0 | — | — | 0 | -152 |
| Cash from financing | 97 | 99 | 59 | 22 | 253 | 267 |
| Net cash flow | 73 | 53 | 9 | -42 | 174 | -16 |
Insider filings
46 filings between Dec 26, 2025 and Sep 25, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$7.00M
17 sales by 5 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 27
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Barrow Robert | — | $3.98M | Sep 25, 2026 |
| Sullivan Mark | — | $1.45M | Sep 25, 2026 |
| Karlin Daniel | — | $1.07M | Sep 25, 2026 |
| Roberts Brandi | — | $259.2K | Sep 25, 2026 |
| Wiley Matthew T. | — | $242.4K | Sep 25, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Roberts Brandi Chief Financial Officer | Sale 10b5-1 plan | 3,377 | $123.5K |
| Sep 25, 2026 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 plan | 14,051 | $513.8K |
| Sep 25, 2026 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 plan | 10,853 | $396.9K |
| Sep 25, 2026 | Wiley Matthew T. Chief Commercial Officer | Sale 10b5-1 plan | 3,097 | $113.3K |
| Sep 25, 2026 | Barrow Robert Chief Executive Officer | Sale 10b5-1 plan | 31,550 | $1.15M |
| Sep 18, 2026 | Vallone Carol A Director | Option exercise | 1,086 | $38.6K |
| Sep 18, 2026 | Krebs Andreas Director | Option exercise | 1,629 | $57.9K |
| Sep 14, 2026 | Sullivan Mark Chief Legal Officer | Award | 125,000 | $0 |
| Sep 14, 2026 | Roberts Brandi Chief Financial Officer | Award | 125,000 | $0 |
| Sep 14, 2026 | Barrow Robert Chief Executive Officer | Award | 750,000 | $0 |
| Sep 14, 2026 | Karlin Daniel Chief Medical Officer | Award | 200,000 | $0 |
| Sep 14, 2026 | Wiley Matthew T. Chief Commercial Officer | Award | 125,000 | $0 |
| Sep 3, 2026 | Barrow Robert Chief Executive Officer | Sale 10b5-1 plan | 19,023 | $721.7K |
| Sep 2, 2026 | Barrow Robert Chief Executive Officer | Award 10b5-1 plan | 40,000 | $0 |
| Aug 12, 2026 | Wiley Matthew T. Chief Commercial Officer | Award | 62,500 | $0 |
| Aug 12, 2026 | Karlin Daniel Chief Medical Officer | Award | 100,000 | $0 |
| Aug 12, 2026 | Sullivan Mark Chief Legal Officer | Award | 62,500 | $0 |
| Aug 12, 2026 | Barrow Robert Chief Executive Officer | Award | 375,000 | $0 |
| Aug 12, 2026 | Roberts Brandi Chief Financial Officer | Award | 62,500 | $0 |
| Jun 25, 2026 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 plan | 10,035 | $451.9K |
| Jun 25, 2026 | Wiley Matthew T. Chief Commercial Officer | Sale 10b5-1 plan | 2,867 | $129.1K |
| Jun 25, 2026 | Barrow Robert Chief Executive Officer | Sale 10b5-1 plan | 29,208 | $1.32M |
| Jun 25, 2026 | Roberts Brandi Chief Financial Officer | Sale 10b5-1 plan | 3,013 | $135.7K |
| Jun 25, 2026 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 plan | 13,008 | $585.8K |
| Jun 22, 2026 | Karlin Daniel Chief Medical Officer | Award | 100,000 | $0 |
| Jun 22, 2026 | Barrow Robert Chief Executive Officer | Award | 375,000 | $0 |
| Jun 22, 2026 | Wiley Matthew T. Chief Commercial Officer | Award | 62,500 | $0 |
| Jun 22, 2026 | Roberts Brandi Chief Financial Officer | Award | 62,500 | $0 |
| Jun 22, 2026 | Sullivan Mark Chief Legal Officer | Award | 62,500 | $0 |
| Jun 11, 2026 | CRYSTAL ROGER Director | Award | 4,666 | $0 |
| Jun 11, 2026 | Bruhn Suzanne Louise Director | Award | 4,666 | $0 |
| Jun 11, 2026 | Adsett Roger Director | Award | 3,555 | $0 |
| Jun 11, 2026 | Krebs Andreas Director | Award | 4,666 | $0 |
| Jun 11, 2026 | Vallone Carol A Director | Award | 4,666 | $0 |
| Jun 11, 2026 | GRYSKA DAVID W Director | Award | 4,666 | $0 |
| Mar 25, 2026 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 plan | 8,018 | $148.1K |
| Mar 25, 2026 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 plan | 10,702 | $197.7K |
| Mar 25, 2026 | Barrow Robert Chief Executive Officer | Sale 10b5-1 plan | 24,431 | $451.2K |
| Feb 3, 2026 | Karlin Daniel Chief Medical Officer | Award | 150,000 | $0 |
| Feb 3, 2026 | Sullivan Mark Chief Legal Officer | Award | 125,000 | $0 |
| Feb 3, 2026 | Barrow Robert Chief Executive Officer | Award | 320,000 | $0 |
| Feb 3, 2026 | Wiley Matthew T. Chief Commercial Officer | Award | 115,000 | $0 |
| Feb 3, 2026 | Roberts Brandi Chief Financial Officer | Award | 150,000 | $0 |
| Dec 26, 2025 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 plan | 11,276 | $148.2K |
| Dec 26, 2025 | Barrow Robert Chief Executive Officer | Sale 10b5-1 plan | 25,791 | $339.1K |
| Dec 26, 2025 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 plan | 5,600 | $73.6K |
| Sep 25, 2025 | Barrow Robert Chief Executive Officer | Sale 10b5-1 plan | 25,797 | $252.0K |
| Sep 25, 2025 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 plan | 11,278 | $110.2K |
| Sep 25, 2025 | Karlin Daniel Chief Medical Officer | Sale 10b5-1 plan | 7,704 | $75.3K |
| Jun 25, 2025 | Sullivan Mark Chief Legal Officer | Sale 10b5-1 plan | 11,491 | $78.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Definium Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Definium Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading